CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Release Date: May-19-10
Credit Expiration Date: May-19-11


Mark A. Frye, MD
Professor of Psychiatry
Medical Director, Integrated Mood Group and Research Program
Mayo Clinic
Rochester, MN

Terence A. Ketter, MD Moderator
Professor of Psychiatry and Behavioral Sciences
Stanford University School of Medicine
Chief, Bipolar Disorders Clinic
Stanford University Hospital and Clinics
Stanford, CA

Martha Sajatovic, MD
Professor of Psychiatry
Case Western Reserve University School of Medicine
Director, Neurological Outcomes Center
University Hospitals
Case Medical Center
Cleveland, OH

Credit Hours



Online Presentation

Program Description

Bipolar disorder is a mental disorder in which patients experience episodes of mood elevation and depression, leading to significant reductions in functional status and quality of life. Bipolar disorder is the sixth leading cause of disability worldwide. Data suggests the lifetime prevalence of bipolar I and II disorders in the general population is 3.7% to 3.9%. Symptoms of bipolar disorder are often masked by other conditions. Very often, patients are not accurately diagnosed for several years, and treatment is delayed or inappropriate treatment is pursued. Appropriate management of bipolar disorder is based on accurate assessment of the individual’s stage of illness and requires acute, continuation, and maintenance phases of pharmacologic and psychotherapeutic treatment.

Psychiatrists are in a critical position to accurately diagnose and effectively treat bipolar disorder. Patients should be recognized and diagnosed as early in the course of their illness as possible in order to benefit the most from early therapeutic interventions. This activity will address specific patient care challenges associated with bipolar disorder, including early and accurate diagnosis, distinguishing between the condition and other symptoms or associated comorbidities, and patient nonadherence to bipolar disorder treatment regimens. Examining these challenges can help psychiatrists and other healthcare providers improve quality of life and longevity for patients with bipolar disorder.

Target Audience

This educational activity is designed to meet the needs of psychiatrists and other healthcare providers involved in the treatment of patients with bipolar disorder.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Explain how to set individualized treatment goals for patients.
  2. Describe strategies for managing the complex patient.
  3. Discuss interventions to address nonadherence to treatment regimens.


It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Dr. Frye discloses that he has received research support from Pfizer; he has also served as a consultant for Bristol-Myers Squibb, Cephalon, Dainippon Sumitomo Pharma, Johnson & Johnson, Medtronic, Ortho McNeil/Janssen Pharmaceuticals, Schering-Plough, Sepracor, and Pfizer.

Dr. Ketter discloses that he has received research support from AstraZeneca, Bristol-Myers Squibb, Cephalon, Eli Lilly & Co., and Pfizer; he has also served as a consultant for AstraZeneca, Astellas Pharmaceuticals, Bristol-Myers Squibb Company, Cephalon, Dainippon Sumitomo Pharma, GlaxoSmithKline, Johnson & Johnson, and Sepracor; and received lecture honoraria from AstraZeneca, GlaxoSmithKline, and Pfizer. Dr. Ketter's spouse is employeed by and owns stock in Johnson & Johnson.

Dr. Sajatovic has received research support from GlaxoSmithKline, AstraZeneca, and Johnson & Johnson; she has also served as a consultant for GlaxoSmithKline.

Credit Statements

PHYSICIANS: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media, Inc. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc. designates this educational activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit is awarded to participants who score 80% or better on the post-test.

This activity will take approximately 60 minutes to complete.

Commercial Support Statements

This activity is supported by an independent grant from Merck.

Certificate Fee



The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, AKH Inc., or Merck. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu